XOMA Royalty to Present at Investor Conferences in March
XOMA Royalty (NASDAQ: XOMA), a biotech royalty aggregator, has announced its Executive Team's upcoming participation in investor conferences scheduled for March 2025. The company will engage in one-on-one investor meetings during these events.
Presentations will be accessible through the investor relations section of XOMA's website (www.xoma.com). Each presentation will remain archived and available for replay on the site for a 90-day period following the respective events.
XOMA Royalty (NASDAQ: XOMA), un aggregatore di royalty biotech, ha annunciato la prossima partecipazione del suo Team Esecutivo a conferenze per investitori programmate per marzo 2025. L'azienda parteciperà a incontri individuali con gli investitori durante questi eventi.
Le presentazioni saranno accessibili attraverso la sezione delle relazioni con gli investitori del sito web di XOMA (www.xoma.com). Ogni presentazione rimarrà archiviata e disponibile per la visione sul sito per un periodo di 90 giorni dopo i rispettivi eventi.
XOMA Royalty (NASDAQ: XOMA), un agregador de regalías biotecnológico, ha anunciado la próxima participación de su Equipo Ejecutivo en conferencias para inversores programadas para marzo de 2025. La empresa participará en reuniones individuales con inversores durante estos eventos.
Las presentaciones estarán disponibles a través de la sección de relaciones con inversores del sitio web de XOMA (www.xoma.com). Cada presentación permanecerá archivada y disponible para su reproducción en el sitio durante un período de 90 días después de los respectivos eventos.
XOMA Royalty (NASDAQ: XOMA), 생명공학 로열티 집합체,는 2025년 3월로 예정된 투자자 회의에 경영진 팀이 참여할 것이라고 발표했습니다. 회사는 이러한 행사 동안 개별 투자자 미팅에 참여할 것입니다.
발표는 XOMA 웹사이트의 투자자 관계 섹션을 통해 접근할 수 있습니다 (www.xoma.com). 각 발표는 해당 이벤트 이후 90일 동안 아카이브되어 사이트에서 재생할 수 있습니다.
XOMA Royalty (NASDAQ: XOMA), un agrégateur de redevances biopharmaceutiques, a annoncé la prochaine participation de son équipe exécutive à des conférences pour investisseurs prévues pour mars 2025. L'entreprise participera à des réunions individuelles avec des investisseurs lors de ces événements.
Les présentations seront accessibles via la section des relations investisseurs du site web de XOMA (www.xoma.com). Chaque présentation restera archivée et disponible en replay sur le site pendant une période de 90 jours suivant les événements respectifs.
XOMA Royalty (NASDAQ: XOMA), ein Biotech-Royalty-Aggregator, hat die bevorstehende Teilnahme seines Executive-Teams an Investorenkonferenzen im März 2025 angekündigt. Das Unternehmen wird während dieser Veranstaltungen eins-zu-eins-Investorenmeetings durchführen.
Präsentationen werden über den Bereich Investor Relations der Website von XOMA (www.xoma.com) zugänglich sein. Jede Präsentation bleibt archiviert und für eine 90-tägige Frist nach den jeweiligen Veranstaltungen auf der Website verfügbar.
- None.
- None.
EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meetings.
| T.D. Cowen 45th Annual Health Care Conference (March 3-5, 2025) | |
| Format: Date: Time: | Corporate presentation Monday, March 3, 2025 11:10AM ET |
| Location: Link: | Boston, MA https://bit.ly/4jUN9w2 |
| Leerink 2025 Global Healthcare Conference (March 9-12, 2025) | |
| Format: | Fireside chat |
| Date: | Monday, March 10, 2025 |
| Time: | 2:20PM ET |
| Location: Link: | Miami Beach, FL https://bit.ly/4hxV1Cg |
XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of each presentation will be available and archived on the site for 90 days after the event.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
| XOMA Investor Contact | XOMA Media Contact |
| Juliane Snowden | Kathy Vincent |
| XOMA Royalty | KV Consulting & Management |
| +1 646-438-9754 | +1 310-403-8951 |
| juliane.snowden@xoma.com | kathy@kathyvincent.com |
FAQ
When will XOMA Royalty present at investor conferences in March 2025?
How long will XOMA's March 2025 investor presentations be available for replay?
Where can investors access XOMA's March 2025 conference presentations?
Will XOMA's management team offer one-on-one meetings during the March 2025 conferences?
